TELA Bio (NASDAQ:TELA) Director Acquires 25,000 Shares

TELA Bio, Inc. (NASDAQ:TELA) Director Joseph Capper bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were acquired at an average cost of $1.02 per share, for a total transaction of $25,500.00. Following the completion of the acquisition, the director directly owned 54,827 shares in the company, valued at $55,923.54. The trade was a 83.82% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

TELA Bio Stock Performance

TELA Bio stock traded up $0.09 during mid-day trading on Wednesday, hitting $1.18. 453,536 shares of the company’s stock traded hands, compared to its average volume of 184,035. The company has a debt-to-equity ratio of 8.82, a current ratio of 2.99 and a quick ratio of 2.38. The firm has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $0.79. TELA Bio, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $1.69. The stock has a market cap of $52.98 million, a price-to-earnings ratio of -1.53 and a beta of 1.36.

TELA Bio (NASDAQ:TELA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $19.29 million during the quarter, compared to analyst estimates of $20.01 million. TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. On average, research analysts expect that TELA Bio, Inc. will post -0.76 EPS for the current fiscal year.

Institutional Investors Weigh In On TELA Bio

Hedge funds and other institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC bought a new stake in shares of TELA Bio in the second quarter valued at about $4,420,586. Stonepine Capital Management LLC bought a new position in TELA Bio during the second quarter worth about $1,996,820. BlackRock Inc. acquired a new stake in TELA Bio in the 2nd quarter worth about $281,000. UP Strategic Wealth Investment Advisors LLC bought a new stake in TELA Bio in the 2nd quarter valued at about $91,000. Finally, Perkins Capital Management Inc. boosted its holdings in TELA Bio by 1.5% in the 1st quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company’s stock valued at $879,000 after purchasing an additional 20,910 shares during the period. Institutional investors and hedge funds own 94.35% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TELA Bio in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $2.20.

TELA Bio Company Profile

TELA Bio, Inc (NASDAQ: TELA) is a commercial?stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.